Some studies have shown that the tumor PD-L1 protein levels can predict the response to PD-1/PD-L1 checkpoint block therapy in cancer patients [20–22], and the nanobody-based imaging can display the PD-L1 expression level in vivo in real-time. This evidence concerns the gene CD274 and neoplasm.